1. Clinical Overview
Pramipexole is a non-ergoline dopamine agonist that selectively stimulates dopamine D2, D3, and D4 receptors. It is a first-line treatment for Parkinson's disease (PD) and is also approved for Restless Legs Syndrome (RLS). The 0.75mg strength is a common therapeutic dose for PD maintenance therapy. It helps manage motor symptoms like bradykinesia, rigidity, and tremor by compensating for the dopamine deficiency in the nigrostriatal pathway.
| Onset | Duration | Bioavailability |
|---|---|---|
| Approximately 2 hours after oral administration. | Approximately 8-12 hours. | Greater than 90%. |
2. Mechanism of Action
Pramipexole exerts its therapeutic effect by directly stimulating postsynaptic dopamine receptors (primarily D2 subfamily: D2, D3, and D4) in the striatum. In Parkinson's disease, it compensates for the depleted dopamine levels resulting from the degeneration of neurons in the substantia nigra. In Restless Legs Syndrome, its mechanism is believed to involve modulation of dopaminergic pathways in the spinal cord and brain.
3. Indications & Uses
- Idiopathic Parkinson's Disease (as monotherapy or adjunct to levodopa)
- Moderate to Severe Primary Restless Legs Syndrome (RLS)
4. Dosage & Administration
Adult Dosage: Parkinson's Disease: Start at 0.125 mg TID. Titrate weekly by 0.125 mg TID to effective dose. Usual maintenance: 1.5-4.5 mg/day in 3 divided doses. 0.75mg TID is a common regimen. RLS: Start at 0.125 mg once daily, 2-3 hours before bedtime. Titrate to 0.75mg once daily if needed.
Administration: Take orally with or without food. Taking with food may reduce nausea. For RLS, take once daily 2-3 hours before bedtime. Do not crush or chew extended-release tablets (if applicable). The 0.75mg dose is typically for immediate-release formulation. Swallow whole with water.
5. Side Effects
Common side effects may include:
- Nausea
- Dizziness
- Somnolence (daytime sleepiness)
- Insomnia
- Constipation
- Peripheral edema
- Headache
- Fatigue
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Levodopa/Carbidopa | Additive therapeutic and adverse effects (dyskinesias, hallucinations, hypotension). | Major |
| Antipsychotics (e.g., Haloperidol, Risperidone) | Antagonizes dopamine agonist effect, reducing efficacy of pramipexole. | Major |
| Other CNS Depressants (Alcohol, Benzodiazepines, Opioids) | Additive sedation and risk of somnolence/sleep attacks. | Major |
| Antihypertensives | Increased risk of orthostatic hypotension. | Moderate |
| Cimetidine | Reduces renal clearance of pramipexole, increasing plasma levels by ~50%. Requires dose reduction. | Moderate |
| Domperidone | May be used to manage nausea without crossing BBB, but monitor. | Minor |
7. Patient Counselling
- DO take exactly as prescribed; do not stop suddenly.
- DO rise slowly from sitting/lying position to avoid dizziness.
- DO inform your doctor about all other medicines, including OTC.
- DONT drive or operate heavy machinery until you know how it affects you.
- DONT consume alcohol while on this medication.
- DO report any new or unusual urges (gambling, shopping, eating, sexual thoughts).
8. Toxicology & Storage
Overdose: Nausea, vomiting, hypotension, agitation, hallucinations, involuntary movements (dyskinesias), cardiac arrhythmias, somnolence progressing to coma.
Storage: Store below 30°C. Protect from light and moisture. Keep in the original blister pack or container. Keep out of reach of children.